A case of an acromegalic patient resistant to the recommended maximum GH receptor antagonist dosage.
BACKGROUND
The competitive GH receptor antagonist pegvisomant is reported to normalise IGF-1 levels in up to 97 % of acromegalic patients at a maximum dosage of 40 mg/d. Description of Case: We present an acromegalic patient resistant to the recommended maximum GH receptor antagonist dosage. The 60-year-old male patient presenting with typical clinical signs of acromegaly has underwent multiple transsphenoidal surgeries and pituitary irradiation, while currently available pharmacological therapies for acromegaly have been exhausted.


RESULTS
Biochemical control of the disease could only be achieved until uptitration of pegvisomant to 60 mg/d which was tolerated well.


CONCLUSIONS
The current treatment algorithm for acromegaly should be modified to treat cases of persistent and uncontrolled disease.
Dept. of Neuroendocrinology, Max-Planck-Institute of Psychiatry, Munich, Germany.
C
C
Dimopoulou
C
C
Sievers
M
M
Bidlingmaier
Gk
G
Stalla
GH receptor antagonist; acromegaly; resistance